Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Sarcoma 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 28Melanoma 9Triple Negative Breast Neoplasms 8Lung Neoplasms 6Carcinoma, Renal Cell 6Squamous Cell Carcinoma of Head and Neck 5Colorectal Neoplasms 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Breast Neoplasms 4Uterine Cervical Neoplasms 3Stomach Neoplasms 3Sarcoma 3Ovarian Neoplasms 3Neoplasms 3Mesothelioma 3Lymphoma 3Head and Neck Neoplasms 3Adenocarcinoma of Lung 3Adenocarcinoma Of Esophagus 3Adenocarcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2NSCLC 2Liver Neoplasms 2Kidney Neoplasms 2Esophageal Squamous Cell Carcinoma 2Endometrial Neoplasms 2Colonic Neoplasms 2

Interventions

pembrolizumab 44Carboplatin 17Pemetrexed 14Paclitaxel 13Cisplatin 13lenvatinib 5Etoposide 5Docetaxel 5epacadostat 4Gemcitabine 4Albumin-Bound Paclitaxel 4durvalumab 3Nivolumab 3130-nm albumin-bound paclitaxel 3spartalizumab 2olaparib 2Saline Solution 2Immune Checkpoint Inhibitors 2Dexamethasone 2Acetaminophen 2sacituzumab govitecan 1ribociclib 1patritumab deruxtecan 1osimertinib 1etoposide phosphate 1efineptakin alfa 1cemiplimab 1camrelizumab 1avelumab 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × spartalizumab × Thoracic × Clear all
NCT04000529 2025-09-30

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Novartis

Phase 1 Terminated
122 enrolled
GastrointestinalHead & NeckSarcomaThoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT02403193 2022-01-12

AdenONCO

Palobiofarma SL

Phase 1 Completed
92 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡